ARVN News

Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders

Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders

Form 8-K

Arvinas Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Arvinas to Participate in Upcoming Investor Conferences

Arvinas to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

Arvinas Announces Appointment of Randy Teel, Ph.D., as President, Chief Executive Officer, and Director

PROTAC Market Shows Accelerated Growth During the Forecast Period (2025-2034) Amid Rising Targeted Therapy Demand | DelveInsight

BioCT Brings Legislators, Academia, and Industry Leaders Together to Strengthen Connecticut’s Life Sciences Sector Ahead of 2026 Session

New nanoparticle technology offers hope for hard-to-treat diseases